Laboratorios Farmaceuticos Rovi (XMAD:ROVI) ROCE %: 6.73% (As of Mar. 2026)


XMAD:ROVI Laboratorios Farmaceuticos Rovi SA XMAD:ROVI
100 GF Score
Price €58.60
GF Value €50.93
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Laboratorios Farmaceuticos Rovi ROCE %?

Laboratorios Farmaceuticos Rovi XMAD:ROVI -1.10% 100 ROCE % is 6.73% as of Mar. 2026. GuruFocus rates XMAD:ROVI with a GF Score™ of 100/100 and a GF Value™ of €50.93 (Modestly Overvalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Laboratorios Farmaceuticos Rovi's annualized ROCE % for the quarter that ended in Mar. 2026 was 6.73%.

Laboratorios Farmaceuticos Rovi  (XMAD:ROVI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Laboratorios Farmaceuticos Rovi ROCE % Related Terms

Laboratorios Farmaceuticos Rovi ROCE % Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi ROCE % Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.89 45.88 37.32 28.18 25.63

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.78 16.04 43.08 30.93 6.73
XMAD:ROVI
100GF Score
Laboratorios Farmaceuticos Rovi SA XMAD:ROVI
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorios Farmaceuticos Rovi ROCE % Calculation

Laboratorios Farmaceuticos Rovi's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=185.827/( ( (832.022 - 156.651) + (955.691 - 181.222) )/ 2 )
=185.827/( (675.371+774.469)/ 2 )
=185.827/724.92
=25.63 %

Laboratorios Farmaceuticos Rovi's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=52.284/( ( (955.691 - 181.222) + (926.315 - 147.53) )/ 2 )
=52.284/( ( 774.469 + 778.785 )/ 2 )
=52.284/776.627
=6.73 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 6.73% mean?
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) has a ROCE % of 6.73% as of Mar. 2026.
Is Laboratorios Farmaceuticos Rovi's ROCE % too high?
Laboratorios Farmaceuticos Rovi's current ROCE % is 6.73%. The Drug Manufacturers industry median ROCE % is 7.00. Laboratorios Farmaceuticos Rovi's value of 6.73% is 3.8% below this industry median. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 100/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's ROCE % compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's ROCE % of 6.73% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Laboratorios Farmaceuticos Rovi's value of 6.73% is 3.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current ROCE % of 6.73% is 3.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current ROCE % is 6.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (XMAD:ROVI) is currently considered Modestly Overvalued. The stock's GF Value™ is €50.93, compared to a current price of €58.60 — trading 15.1% above its estimated fair value. The current ROCE % is 6.73% and 3.8% below the Drug Manufacturers industry median of 7.00. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (XMAD:ROVI), the current ROCE % is 6.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of €58.60 is trading 15.1% above its estimated GF Value™ of €50.93. GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.

Key valuation signals for XMAD:ROVI:

  • ROCE %: 6.73%
  • GF Value™: €50.93 vs. price of €58.60 (15.1% above fair value)
  • GF Score™: 100/100 with 1 warning sign
  • Industry Position: 3.8% below the Drug Manufacturers median

No single metric tells the full story. See the XMAD:ROVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
100GF Score

Get the complete analysis for XMAD:ROVI

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€58.60
Price
€50.93
GF Value